drugset / Trial / NCT05924841
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.
Timeline
- Start
- 2023-11-10
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izalontamab Brengitecan | Unknown | — | Intravenous |
| Subject | SI-B003 | Monoclonal antibody | — | Intravenous |